



KVB Kunlun
昆 侖 國 際

TRADINGSTAR

Stock Broking Team: Jimmy Koh, Eric Zheng, Coral Jin, Edison Zhao, Edward Lee
NZX Advisors: Greg Boland, Jimmy Koh
Tel: 09-3598999 Fax: 09-3598990 Email: nzinvest@kvbkunlun.com

Today's HOT stock

03 September 2010

Anavex Life Sciences Corp. – AVXL.OB

Anavex Life Sciences Corp. (Anavex), incorporated on January 24, 2004, is a development-stage biopharmaceutical company engaged in the discovery and development of drug targets for the treatment of cancer and diseases of the central nervous system. The current market price is USD 3.67.

Experts are increasingly agreeing that the process of Alzheimer's begins very early — perhaps in our thirties. As Western populations age, this disease will continue to command a huge amount of attention. According to its Anavex's Chairman Dr. Durrant, "Anavex Life Sciences has generated evidence of improving and reversing the memory and learning deficits of animals with Alzheimer's in its animal studies. Human trials are scheduled to start later this year." The company has successfully finished the initial phase of the program, and has received encouraging data. With recent setbacks in Alzheimer's studies, Anavex stands out as the only one in the right direction to find a cure for disease.

Source: www.finance.yahoo.com, www.seekingalpha.com

This commentary is prepared by Jimmy Koh, Manager, and Investment Sales. A copy of his Investment Adviser's Disclosure Statement can be obtained from www.kvbkunlun.com.

This document is produced by KVB Kunlun NZ Limited based on information available at the time of publishing.

We believe that the information in this document is correct and any opinions, conclusions or recommendations are reasonably held or made as at the time of its compilation, but no warranty is made as to accuracy, reliability or completeness. To the extent permitted by law, neither KVB Kunlun NZ Limited nor any of its affiliates accept liability to any person for loss or damage arising from the use of this document. All information, prices and opinions are subject to change without prior notice.

The information contained in this document does not constitute financial or investment advice and has been prepared without taking account of the objectives, financial situation or needs of any particular individual. For this reason, any individual should, before acting on the information in this document, consider the appropriateness of the information, having regard to the individual's objective, financial situation and needs and, if necessary, seek appropriate professional advice.

Investment products are issued by KVB Kunlun New Zealand Limited. The risk of loss in leveraged foreign exchange, CFDs and other derivatives trading can be substantial. Investors should therefore carefully consider whether such trading is suitable in light of their own financial position and investment objectives and if necessary seek appropriate professional advice. Product Disclosure Statements are available on request and free of charge from KVB Kunlun and prospective clients are advised to read these carefully before making any investment decision.

Investment Adviser and Investment Broker Disclosure Statements (under the Securities Markets Act 1988) for KVB Kunlun NZ Limited or KVB Kunlun Pty Ltd, and your adviser are available on request and free of charge. Please contact your adviser to obtain a copy.

This document is approved and distributed in Australia by KVB Kunlun Pty Ltd (ACN 101829467 and Australian Financial Services (AFS) License No: 226602), an affiliated company of KVB Kunlun NZ Limited. This document is approved and distributed in Hong Kong by KVB Kunlun International (HK) Ltd and KVB Kunlun Securities (HK) Ltd, an affiliated company of KVB Kunlun NZ Limited. This document does not purport to be a complete statement or summary. KVB Kunlun NZ Ltd and its affiliates have effected or may effect transactions for their own account and behalf of its customers in any investments or related investments referred to in this document.